title: Stage III ovarian carcinoma: an analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage.
abstract: OBJECTIVE
  Patients with persistent disease found at laparotomy following platinum-based chemotherapy for Stage III ovarian carcinoma have a remote chance of cure with second-line chemotherapy or conventional radiotherapy. To decrease relapse rates and improve tolerance, we have used twice-daily radiotherapy in 28 such patients.
  
  
  METHODS
  Twenty-eight patients with Stage III epithelial ovarian carcinoma were treated with curative intent at the University of Florida with hyperfractionated, continuous-course radiotherapy for persistent disease at laparotomy after administration of platinum-based chemotherapy. All patients received .8 Gy per fraction, twice daily, to a mean total dose of 30.2 Gy to the whole abdomen and pelvis; 20 patients had additional radiotherapy to the pelvis (mean, 14.54 Gy). All patients had undergone two to four (mean, 2.6) laparotomies for ovarian carcinoma and had received 6-28 (mean, 12) cycles of chemotherapy before irradiation.
  
  
  RESULTS
  With a 2-year minimum follow-up, survival rates at 1, 2, and 5 years were as follows: absolute survival, 79%, 50%, 21%; relapse-free survival, 52%, 36%, 19%. For the 11 patients with no evidence of gross residual disease after the second-look laparotomy, the absolute survival rates were 100%, 73%, and 27%. This was superior to the rates of 65%, 34%, and 18% for the 17 patients who had gross residual disease. Only two patients required treatment breaks. Four patients required surgical intervention for small-bowel obstruction, which in two cases revealed recurrent disease. Two patients died of treatment-related complications. Twenty-two of 23 failures occurred in the abdomen and/or pelvis.
  
  
  CONCLUSIONS
  Although most patients eventually relapse, a small percentage have had a prolonged disease-free interval. Since treatment was relatively well tolerated, escalation of the dose of hyperfractionated abdominopelvic irradiation is being investigated.
authors.affiliation: Department of Radiation Oncology, University of Florida College of Medicine, Gainesville.
authors.forename: D A
authors.initials: DA
authors.lastname: Fein
authors.forename: L S
authors.initials: LS
authors.lastname: Morgan
authors.forename: R B
authors.initials: RB
authors.lastname: Marcus
authors.forename: W M
authors.initials: WM
authors.lastname: Mendenhall
authors.forename: M D
authors.initials: MD
authors.lastname: Sombeck
authors.forename: D E
authors.initials: DE
authors.lastname: Freeman
authors.forename: R R
authors.initials: RR
authors.lastname: Million
mesh_terms: D002277:Carcinoma / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects; D016019:Survival Analysis; D013997:Time Factors